Storm of soluble immune checkpoints associated with disease severity of COVID-19.
Identifieur interne : 000203 ( Main/Exploration ); précédent : 000202; suivant : 000204Storm of soluble immune checkpoints associated with disease severity of COVID-19.
Auteurs : Yaxian Kong [République populaire de Chine] ; Yu Wang [République populaire de Chine] ; Xueying Wu [République populaire de Chine] ; Junyan Han [République populaire de Chine] ; Guoli Li [République populaire de Chine] ; Mingxi Hua [République populaire de Chine] ; Kai Han [République populaire de Chine] ; Henghui Zhang [République populaire de Chine] ; Ang Li [République populaire de Chine] ; Hui Zeng [République populaire de Chine]Source :
- Signal transduction and targeted therapy [ 2059-3635 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Analyse de survie (MeSH), Antigènes CD137 (génétique), Antigènes CD137 (immunologie), Antigènes CD137 (sang), Antigènes CD27 (génétique), Antigènes CD27 (immunologie), Antigènes CD27 (sang), Betacoronavirus (immunologie), Betacoronavirus (pathogénicité), Femelle (MeSH), Humains (MeSH), Indice de gravité de la maladie (MeSH), Indoleamine-pyrrole 2,3,-dioxygenase (génétique), Indoleamine-pyrrole 2,3,-dioxygenase (immunologie), Indoleamine-pyrrole 2,3,-dioxygenase (sang), Infections à coronavirus (diagnostic), Infections à coronavirus (génétique), Infections à coronavirus (immunologie), Infections à coronavirus (mortalité), Lymphocytes T (immunologie), Lymphocytes T (virologie), Lymphopénie (diagnostic), Lymphopénie (génétique), Lymphopénie (immunologie), Lymphopénie (mortalité), Marqueurs biologiques (sang), Mâle (MeSH), Numération des lymphocytes (MeSH), Pandémies (MeSH), Pneumopathie virale (diagnostic), Pneumopathie virale (génétique), Pneumopathie virale (immunologie), Pneumopathie virale (mortalité), Récepteur cellulaire-2 du virus de l'hépatite A (génétique), Récepteur cellulaire-2 du virus de l'hépatite A (immunologie), Récepteur cellulaire-2 du virus de l'hépatite A (sang), Régulation de l'expression des gènes (immunologie), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Études rétrospectives (MeSH), Évolution de la maladie (MeSH).
- MESH :
- diagnostic : Infections à coronavirus, Lymphopénie, Pneumopathie virale.
- génétique : Antigènes CD137, Antigènes CD27, Indoleamine-pyrrole 2,3,-dioxygenase, Infections à coronavirus, Lymphopénie, Pneumopathie virale, Récepteur cellulaire-2 du virus de l'hépatite A.
- immunologie : Antigènes CD137, Antigènes CD27, Betacoronavirus, Indoleamine-pyrrole 2,3,-dioxygenase, Infections à coronavirus, Lymphocytes T, Lymphopénie, Pneumopathie virale, Récepteur cellulaire-2 du virus de l'hépatite A, Régulation de l'expression des gènes.
- mortalité : Infections à coronavirus, Lymphopénie, Pneumopathie virale.
- pathogénicité : Betacoronavirus.
- sang : Antigènes CD137, Antigènes CD27, Indoleamine-pyrrole 2,3,-dioxygenase, Marqueurs biologiques, Récepteur cellulaire-2 du virus de l'hépatite A.
- virologie : Lymphocytes T.
- Adulte, Adulte d'âge moyen, Analyse de survie, Femelle, Humains, Indice de gravité de la maladie, Mâle, Numération des lymphocytes, Pandémies, Sujet âgé, Sujet âgé de 80 ans ou plus, Études rétrospectives, Évolution de la maladie.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Betacoronavirus (immunology), Betacoronavirus (pathogenicity), Biomarkers (blood), Coronavirus Infections (diagnosis), Coronavirus Infections (genetics), Coronavirus Infections (immunology), Coronavirus Infections (mortality), Cytokine Release Syndrome (diagnosis), Cytokine Release Syndrome (genetics), Cytokine Release Syndrome (immunology), Cytokine Release Syndrome (mortality), Disease Progression (MeSH), Female (MeSH), Gene Expression Regulation (immunology), Hepatitis A Virus Cellular Receptor 2 (blood), Hepatitis A Virus Cellular Receptor 2 (genetics), Hepatitis A Virus Cellular Receptor 2 (immunology), Humans (MeSH), Indoleamine-Pyrrole 2,3,-Dioxygenase (blood), Indoleamine-Pyrrole 2,3,-Dioxygenase (genetics), Indoleamine-Pyrrole 2,3,-Dioxygenase (immunology), Lymphocyte Count (MeSH), Lymphopenia (diagnosis), Lymphopenia (genetics), Lymphopenia (immunology), Lymphopenia (mortality), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Pneumonia, Viral (diagnosis), Pneumonia, Viral (genetics), Pneumonia, Viral (immunology), Pneumonia, Viral (mortality), Retrospective Studies (MeSH), Severity of Illness Index (MeSH), Survival Analysis (MeSH), T-Lymphocytes (immunology), T-Lymphocytes (virology), Tumor Necrosis Factor Receptor Superfamily, Member 7 (blood), Tumor Necrosis Factor Receptor Superfamily, Member 7 (genetics), Tumor Necrosis Factor Receptor Superfamily, Member 7 (immunology), Tumor Necrosis Factor Receptor Superfamily, Member 9 (blood), Tumor Necrosis Factor Receptor Superfamily, Member 9 (genetics), Tumor Necrosis Factor Receptor Superfamily, Member 9 (immunology).
- MESH :
- chemical , blood : Biomarkers, Hepatitis A Virus Cellular Receptor 2, Indoleamine-Pyrrole 2,3,-Dioxygenase, Tumor Necrosis Factor Receptor Superfamily, Member 7, Tumor Necrosis Factor Receptor Superfamily, Member 9.
- diagnosis : Coronavirus Infections, Cytokine Release Syndrome, Lymphopenia, Pneumonia, Viral.
- genetics : Coronavirus Infections, Cytokine Release Syndrome, Hepatitis A Virus Cellular Receptor 2, Indoleamine-Pyrrole 2,3,-Dioxygenase, Lymphopenia, Pneumonia, Viral, Tumor Necrosis Factor Receptor Superfamily, Member 7, Tumor Necrosis Factor Receptor Superfamily, Member 9.
- immunology : Betacoronavirus, Coronavirus Infections, Cytokine Release Syndrome, Gene Expression Regulation, Hepatitis A Virus Cellular Receptor 2, Indoleamine-Pyrrole 2,3,-Dioxygenase, Lymphopenia, Pneumonia, Viral, T-Lymphocytes, Tumor Necrosis Factor Receptor Superfamily, Member 7, Tumor Necrosis Factor Receptor Superfamily, Member 9.
- mortality : Coronavirus Infections, Cytokine Release Syndrome, Lymphopenia, Pneumonia, Viral.
- pathogenicity : Betacoronavirus.
- virology : T-Lymphocytes.
- Adult, Aged, Aged, 80 and over, Disease Progression, Female, Humans, Lymphocyte Count, Male, Middle Aged, Pandemics, Retrospective Studies, Severity of Illness Index, Survival Analysis.
DOI: 10.1038/s41392-020-00308-2
PubMed: 32895366
PubMed Central: PMC7475713
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Storm of soluble immune checkpoints associated with disease severity of COVID-19.</title><author><name sortKey="Kong, Yaxian" sort="Kong, Yaxian" uniqKey="Kong Y" first="Yaxian" last="Kong">Yaxian Kong</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015</wicri:regionArea><wicri:noRegion>100015</wicri:noRegion></affiliation></author><author><name sortKey="Wang, Yu" sort="Wang, Yu" uniqKey="Wang Y" first="Yu" last="Wang">Yu Wang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Respiratory Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015</wicri:regionArea><wicri:noRegion>100015</wicri:noRegion></affiliation></author><author><name sortKey="Wu, Xueying" sort="Wu, Xueying" uniqKey="Wu X" first="Xueying" last="Wu">Xueying Wu</name><affiliation wicri:level="1"><nlm:affiliation>Immupeutics Medicine Institute, Beijing, 100191, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Immupeutics Medicine Institute, Beijing, 100191</wicri:regionArea><wicri:noRegion>100191</wicri:noRegion></affiliation></author><author><name sortKey="Han, Junyan" sort="Han, Junyan" uniqKey="Han J" first="Junyan" last="Han">Junyan Han</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015</wicri:regionArea><wicri:noRegion>100015</wicri:noRegion></affiliation></author><author><name sortKey="Li, Guoli" sort="Li, Guoli" uniqKey="Li G" first="Guoli" last="Li">Guoli Li</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015</wicri:regionArea><wicri:noRegion>100015</wicri:noRegion></affiliation></author><author><name sortKey="Hua, Mingxi" sort="Hua, Mingxi" uniqKey="Hua M" first="Mingxi" last="Hua">Mingxi Hua</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015</wicri:regionArea><wicri:noRegion>100015</wicri:noRegion></affiliation></author><author><name sortKey="Han, Kai" sort="Han, Kai" uniqKey="Han K" first="Kai" last="Han">Kai Han</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015</wicri:regionArea><wicri:noRegion>100015</wicri:noRegion></affiliation></author><author><name sortKey="Zhang, Henghui" sort="Zhang, Henghui" uniqKey="Zhang H" first="Henghui" last="Zhang">Henghui Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. zhhbao@ccmu.edu.cn.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015</wicri:regionArea><wicri:noRegion>100015</wicri:noRegion></affiliation></author><author><name sortKey="Li, Ang" sort="Li, Ang" uniqKey="Li A" first="Ang" last="Li">Ang Li</name><affiliation wicri:level="1"><nlm:affiliation>Department of Intensive Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. liang@ccmu.edu.cn.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Intensive Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015</wicri:regionArea><wicri:noRegion>100015</wicri:noRegion></affiliation></author><author><name sortKey="Zeng, Hui" sort="Zeng, Hui" uniqKey="Zeng H" first="Hui" last="Zeng">Hui Zeng</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. zenghui@ccmu.edu.cn.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015</wicri:regionArea><wicri:noRegion>100015</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32895366</idno><idno type="pmid">32895366</idno><idno type="doi">10.1038/s41392-020-00308-2</idno><idno type="pmc">PMC7475713</idno><idno type="wicri:Area/Main/Corpus">000320</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000320</idno><idno type="wicri:Area/Main/Curation">000320</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000320</idno><idno type="wicri:Area/Main/Exploration">000320</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Storm of soluble immune checkpoints associated with disease severity of COVID-19.</title><author><name sortKey="Kong, Yaxian" sort="Kong, Yaxian" uniqKey="Kong Y" first="Yaxian" last="Kong">Yaxian Kong</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015</wicri:regionArea><wicri:noRegion>100015</wicri:noRegion></affiliation></author><author><name sortKey="Wang, Yu" sort="Wang, Yu" uniqKey="Wang Y" first="Yu" last="Wang">Yu Wang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Respiratory Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015</wicri:regionArea><wicri:noRegion>100015</wicri:noRegion></affiliation></author><author><name sortKey="Wu, Xueying" sort="Wu, Xueying" uniqKey="Wu X" first="Xueying" last="Wu">Xueying Wu</name><affiliation wicri:level="1"><nlm:affiliation>Immupeutics Medicine Institute, Beijing, 100191, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Immupeutics Medicine Institute, Beijing, 100191</wicri:regionArea><wicri:noRegion>100191</wicri:noRegion></affiliation></author><author><name sortKey="Han, Junyan" sort="Han, Junyan" uniqKey="Han J" first="Junyan" last="Han">Junyan Han</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015</wicri:regionArea><wicri:noRegion>100015</wicri:noRegion></affiliation></author><author><name sortKey="Li, Guoli" sort="Li, Guoli" uniqKey="Li G" first="Guoli" last="Li">Guoli Li</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015</wicri:regionArea><wicri:noRegion>100015</wicri:noRegion></affiliation></author><author><name sortKey="Hua, Mingxi" sort="Hua, Mingxi" uniqKey="Hua M" first="Mingxi" last="Hua">Mingxi Hua</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015</wicri:regionArea><wicri:noRegion>100015</wicri:noRegion></affiliation></author><author><name sortKey="Han, Kai" sort="Han, Kai" uniqKey="Han K" first="Kai" last="Han">Kai Han</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015</wicri:regionArea><wicri:noRegion>100015</wicri:noRegion></affiliation></author><author><name sortKey="Zhang, Henghui" sort="Zhang, Henghui" uniqKey="Zhang H" first="Henghui" last="Zhang">Henghui Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. zhhbao@ccmu.edu.cn.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015</wicri:regionArea><wicri:noRegion>100015</wicri:noRegion></affiliation></author><author><name sortKey="Li, Ang" sort="Li, Ang" uniqKey="Li A" first="Ang" last="Li">Ang Li</name><affiliation wicri:level="1"><nlm:affiliation>Department of Intensive Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. liang@ccmu.edu.cn.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Intensive Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015</wicri:regionArea><wicri:noRegion>100015</wicri:noRegion></affiliation></author><author><name sortKey="Zeng, Hui" sort="Zeng, Hui" uniqKey="Zeng H" first="Hui" last="Zeng">Hui Zeng</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. zenghui@ccmu.edu.cn.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015</wicri:regionArea><wicri:noRegion>100015</wicri:noRegion></affiliation></author></analytic><series><title level="j">Signal transduction and targeted therapy</title><idno type="eISSN">2059-3635</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Betacoronavirus (immunology)</term><term>Betacoronavirus (pathogenicity)</term><term>Biomarkers (blood)</term><term>Coronavirus Infections (diagnosis)</term><term>Coronavirus Infections (genetics)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (mortality)</term><term>Cytokine Release Syndrome (diagnosis)</term><term>Cytokine Release Syndrome (genetics)</term><term>Cytokine Release Syndrome (immunology)</term><term>Cytokine Release Syndrome (mortality)</term><term>Disease Progression (MeSH)</term><term>Female (MeSH)</term><term>Gene Expression Regulation (immunology)</term><term>Hepatitis A Virus Cellular Receptor 2 (blood)</term><term>Hepatitis A Virus Cellular Receptor 2 (genetics)</term><term>Hepatitis A Virus Cellular Receptor 2 (immunology)</term><term>Humans (MeSH)</term><term>Indoleamine-Pyrrole 2,3,-Dioxygenase (blood)</term><term>Indoleamine-Pyrrole 2,3,-Dioxygenase (genetics)</term><term>Indoleamine-Pyrrole 2,3,-Dioxygenase (immunology)</term><term>Lymphocyte Count (MeSH)</term><term>Lymphopenia (diagnosis)</term><term>Lymphopenia (genetics)</term><term>Lymphopenia (immunology)</term><term>Lymphopenia (mortality)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (diagnosis)</term><term>Pneumonia, Viral (genetics)</term><term>Pneumonia, Viral (immunology)</term><term>Pneumonia, Viral (mortality)</term><term>Retrospective Studies (MeSH)</term><term>Severity of Illness Index (MeSH)</term><term>Survival Analysis (MeSH)</term><term>T-Lymphocytes (immunology)</term><term>T-Lymphocytes (virology)</term><term>Tumor Necrosis Factor Receptor Superfamily, Member 7 (blood)</term><term>Tumor Necrosis Factor Receptor Superfamily, Member 7 (genetics)</term><term>Tumor Necrosis Factor Receptor Superfamily, Member 7 (immunology)</term><term>Tumor Necrosis Factor Receptor Superfamily, Member 9 (blood)</term><term>Tumor Necrosis Factor Receptor Superfamily, Member 9 (genetics)</term><term>Tumor Necrosis Factor Receptor Superfamily, Member 9 (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Analyse de survie (MeSH)</term><term>Antigènes CD137 (génétique)</term><term>Antigènes CD137 (immunologie)</term><term>Antigènes CD137 (sang)</term><term>Antigènes CD27 (génétique)</term><term>Antigènes CD27 (immunologie)</term><term>Antigènes CD27 (sang)</term><term>Betacoronavirus (immunologie)</term><term>Betacoronavirus (pathogénicité)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Indice de gravité de la maladie (MeSH)</term><term>Indoleamine-pyrrole 2,3,-dioxygenase (génétique)</term><term>Indoleamine-pyrrole 2,3,-dioxygenase (immunologie)</term><term>Indoleamine-pyrrole 2,3,-dioxygenase (sang)</term><term>Infections à coronavirus (diagnostic)</term><term>Infections à coronavirus (génétique)</term><term>Infections à coronavirus (immunologie)</term><term>Infections à coronavirus (mortalité)</term><term>Lymphocytes T (immunologie)</term><term>Lymphocytes T (virologie)</term><term>Lymphopénie (diagnostic)</term><term>Lymphopénie (génétique)</term><term>Lymphopénie (immunologie)</term><term>Lymphopénie (mortalité)</term><term>Marqueurs biologiques (sang)</term><term>Mâle (MeSH)</term><term>Numération des lymphocytes (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (diagnostic)</term><term>Pneumopathie virale (génétique)</term><term>Pneumopathie virale (immunologie)</term><term>Pneumopathie virale (mortalité)</term><term>Récepteur cellulaire-2 du virus de l'hépatite A (génétique)</term><term>Récepteur cellulaire-2 du virus de l'hépatite A (immunologie)</term><term>Récepteur cellulaire-2 du virus de l'hépatite A (sang)</term><term>Régulation de l'expression des gènes (immunologie)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Études rétrospectives (MeSH)</term><term>Évolution de la maladie (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term><term>Hepatitis A Virus Cellular Receptor 2</term><term>Indoleamine-Pyrrole 2,3,-Dioxygenase</term><term>Tumor Necrosis Factor Receptor Superfamily, Member 7</term><term>Tumor Necrosis Factor Receptor Superfamily, Member 9</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term><term>Cytokine Release Syndrome</term><term>Lymphopenia</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à coronavirus</term><term>Lymphopénie</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Coronavirus Infections</term><term>Cytokine Release Syndrome</term><term>Hepatitis A Virus Cellular Receptor 2</term><term>Indoleamine-Pyrrole 2,3,-Dioxygenase</term><term>Lymphopenia</term><term>Pneumonia, Viral</term><term>Tumor Necrosis Factor Receptor Superfamily, Member 7</term><term>Tumor Necrosis Factor Receptor Superfamily, Member 9</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Antigènes CD137</term><term>Antigènes CD27</term><term>Indoleamine-pyrrole 2,3,-dioxygenase</term><term>Infections à coronavirus</term><term>Lymphopénie</term><term>Pneumopathie virale</term><term>Récepteur cellulaire-2 du virus de l'hépatite A</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes CD137</term><term>Antigènes CD27</term><term>Betacoronavirus</term><term>Indoleamine-pyrrole 2,3,-dioxygenase</term><term>Infections à coronavirus</term><term>Lymphocytes T</term><term>Lymphopénie</term><term>Pneumopathie virale</term><term>Récepteur cellulaire-2 du virus de l'hépatite A</term><term>Régulation de l'expression des gènes</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Betacoronavirus</term><term>Coronavirus Infections</term><term>Cytokine Release Syndrome</term><term>Gene Expression Regulation</term><term>Hepatitis A Virus Cellular Receptor 2</term><term>Indoleamine-Pyrrole 2,3,-Dioxygenase</term><term>Lymphopenia</term><term>Pneumonia, Viral</term><term>T-Lymphocytes</term><term>Tumor Necrosis Factor Receptor Superfamily, Member 7</term><term>Tumor Necrosis Factor Receptor Superfamily, Member 9</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coronavirus Infections</term><term>Cytokine Release Syndrome</term><term>Lymphopenia</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections à coronavirus</term><term>Lymphopénie</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Antigènes CD137</term><term>Antigènes CD27</term><term>Indoleamine-pyrrole 2,3,-dioxygenase</term><term>Marqueurs biologiques</term><term>Récepteur cellulaire-2 du virus de l'hépatite A</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Lymphocytes T</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>T-Lymphocytes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Lymphocyte Count</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Survival Analysis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de survie</term><term>Femelle</term><term>Humains</term><term>Indice de gravité de la maladie</term><term>Mâle</term><term>Numération des lymphocytes</term><term>Pandémies</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études rétrospectives</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32895366</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-3635</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>09</Month><Day>07</Day></PubDate></JournalIssue><Title>Signal transduction and targeted therapy</Title><ISOAbbreviation>Signal Transduct Target Ther</ISOAbbreviation></Journal><ArticleTitle>Storm of soluble immune checkpoints associated with disease severity of COVID-19.</ArticleTitle><Pagination><MedlinePgn>192</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41392-020-00308-2</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Yaxian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xueying</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Immupeutics Medicine Institute, Beijing, 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Junyan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Guoli</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hua</LastName><ForeName>Mingxi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Henghui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. zhhbao@ccmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ang</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. liang@ccmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Hui</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7456-6061</Identifier><AffiliationInfo><Affiliation>Institute of Infectious Diseases, Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. zenghui@ccmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZYLX201802</GrantID><Agency>Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Signal Transduct Target Ther</MedlineTA><NlmUniqueID>101676423</NlmUniqueID><ISSNLinking>2059-3635</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C448908">HAVCR2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000072597">Hepatitis A Virus Cellular Receptor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050503">Indoleamine-Pyrrole 2,3,-Dioxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C505714">TNFRSF9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018127">Tumor Necrosis Factor Receptor Superfamily, Member 7</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053261">Tumor Necrosis Factor Receptor Superfamily, Member 9</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C576710">indoleamine 2,3-dioxygenase 1, human</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072597" MajorTopicYN="N">Hepatitis A Virus Cellular Receptor 2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050503" MajorTopicYN="N">Indoleamine-Pyrrole 2,3,-Dioxygenase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008231" MajorTopicYN="N">Lymphopenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018127" MajorTopicYN="N">Tumor Necrosis Factor Receptor Superfamily, Member 7</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053261" MajorTopicYN="N">Tumor Necrosis Factor Receptor Superfamily, Member 9</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>07</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>08</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>08</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>8</Day><Hour>5</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32895366</ArticleId><ArticleId IdType="doi">10.1038/s41392-020-00308-2</ArticleId><ArticleId IdType="pii">10.1038/s41392-020-00308-2</ArticleId><ArticleId IdType="pmc">PMC7475713</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Invest. 2020 May 1;130(5):2620-2629</Citation><ArticleIdList><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2020 Aug 18;53(2):442-455.e4</Citation><ArticleIdList><ArticleId IdType="pubmed">32668194</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunother Cancer. 2018 Nov 27;6(1):132</Citation><ArticleIdList><ArticleId IdType="pubmed">30482248</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2020 Aug;26(8):1218-1223</Citation><ArticleIdList><ArticleId IdType="pubmed">32581323</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Immunol. 2020 May;17(5):541-543</Citation><ArticleIdList><ArticleId IdType="pubmed">32203186</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Kong, Yaxian" sort="Kong, Yaxian" uniqKey="Kong Y" first="Yaxian" last="Kong">Yaxian Kong</name></noRegion><name sortKey="Han, Junyan" sort="Han, Junyan" uniqKey="Han J" first="Junyan" last="Han">Junyan Han</name><name sortKey="Han, Kai" sort="Han, Kai" uniqKey="Han K" first="Kai" last="Han">Kai Han</name><name sortKey="Hua, Mingxi" sort="Hua, Mingxi" uniqKey="Hua M" first="Mingxi" last="Hua">Mingxi Hua</name><name sortKey="Li, Ang" sort="Li, Ang" uniqKey="Li A" first="Ang" last="Li">Ang Li</name><name sortKey="Li, Guoli" sort="Li, Guoli" uniqKey="Li G" first="Guoli" last="Li">Guoli Li</name><name sortKey="Wang, Yu" sort="Wang, Yu" uniqKey="Wang Y" first="Yu" last="Wang">Yu Wang</name><name sortKey="Wu, Xueying" sort="Wu, Xueying" uniqKey="Wu X" first="Xueying" last="Wu">Xueying Wu</name><name sortKey="Zeng, Hui" sort="Zeng, Hui" uniqKey="Zeng H" first="Hui" last="Zeng">Hui Zeng</name><name sortKey="Zhang, Henghui" sort="Zhang, Henghui" uniqKey="Zhang H" first="Henghui" last="Zhang">Henghui Zhang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000203 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000203 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32895366
|texte= Storm of soluble immune checkpoints associated with disease severity of COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32895366" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |